Table 1.
Baseline characteristics of poor mobilizers andcontrols
| Total cohort |
Total cohort |
NGS cohort |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Successful mobilizers |
Poor mobilizers |
P value | n | Matched controls |
Poor mobilizers |
P value | n | ||
| n = 776 | n = 670 | n = 106 | n = 89 | n = 90 | |||||
| Male sex - n (%) | 499 (64.3%) | 423 (63.1%) | 76 (71.7%) | .109 | 776 | 64 (71.9%) | 65 (72.2%) | 1.000 | 179 |
| Age at apheresis (y) – median (IQR) | 59.0 (52.0-63.0) | 59.0 (52.0-63.0) | 59.0 (52.0-64.0) | .453 | 776 | 59.0 (52.0-63.0) | 59.0 (51.0-64.0) | .948 | 179 |
| Major histological subtype - n (%) | .036 | 776 | .845 | 179 | |||||
| Aggressive B-cell lymphoma | 127 (16.4%) | 104 (15.5%) | 23 (21.7%) | 21 (23.6%) | 19 (21.1%) | ||||
| Follicular lymphoma | 22 (2.84%) | 18 (2.69%) | 4 (3.77%) | 4 (4.49%) | 4 (4.44%) | ||||
| Hodgkin lymphoma | 51 (6.57%) | 43 (6.42%) | 8 (7.55%) | 8 (8.99%) | 8 (8.89%) | ||||
| Mantle cell lymphoma | 78 (10.1%) | 67 (10.0%) | 11 (10.4%) | 11 (12.4%) | 11 (12.2%) | ||||
| Other non-Hodgkin lymphoma | 11 (1.42%) | 6 (0.90%) | 5 (4.72%) | 0 (0.00%) | 3 (3.33%) | ||||
| Plasma cell dyscrasia | 433 (55.8%) | 383 (57.2%) | 50 (47.2%) | 42 (47.2%) | 42 (46.7%) | ||||
| T-cell lymphoma | 54 (6.96%) | 49 (7.31%) | 5 (4.72%) | 3 (3.37%) | 3 (3.33%) | ||||
| Remission status at the time of mobilization - n (%) | 179 | ||||||||
| CR | 35 (39%) | 35 (39%) | |||||||
| PR or VGPR | 50 (56%) | 46 (51%) | |||||||
| Stable disease or PD | 4 (4%) | 9 (10%) | |||||||
| Bone marrow infiltration - n∗ | 2 | 5 | 43 | ||||||
| Number of lines of therapy – median (IQR) | 2.00 [1.00-2.00] | 2.00 [1.00-2.00] | .076 | 179 | |||||
| Chemomobilization regimen - n (%) | .269 | 179 | |||||||
| BV-DHAC/DHAP | 0 (0.00%) | 3 (3.33%) | |||||||
| CAD | 7 (7.87%) | 3 (3.33%) | |||||||
| CHO(E)P | 3 (3.37%) | 2 (2.22%) | |||||||
| Cyclophosphamide | 35 (39.3%) | 44 (48.9%) | |||||||
| (R)-DHAP or (R)-VIM | 29 (32.6%) | 20 (22.2%) | |||||||
| HD ARA-C | 10 (11.2%) | 11 (12.2%) | |||||||
| Other | 5 (5.62%) | 7 (7.77%) | |||||||
| CD34 yield (106/kg) - median (IQR) | 9.78 (6.70-13.6) | 10.3 (7.37-14.1) | 5.42 (3.68-7.880) | <.001 | 751 | 10.4 (7.76-12.90) | 5.58 (3.54-7.81) | <.001 | 157 |
| Number of apheresis days - median (IQR) | 1.00 (1.00-2.00) | 1.00 (1.00-2.00) | 2.00 (1.00-3.00) | <.001 | 776 | 1.00 (1.00-2.00) | 2.00 (1.00-3.00) | .007 | 179 |
| Allogeneic transplantation - n (%) | 101 (13.0%) | 86 (12.8%) | 15 (14.2%) | .827 | 776 | 11 (12.4%) | 12 (13.3%) | 1.000 | 179 |
| Peripheral blood counts† - mean (SD) | |||||||||
| Hemoglobin level (g/dL) | 12.0 (1.54) | 11.5 (1.75) | .046 | 179 | |||||
| Platelet count (×109/L) | 273 (94.3) | 239 (113) | .032 | 179 | |||||
| WBC (×109/L) | 7.05 (3.36) | 5.83 (3.27) | .015 | 179 | |||||
| ANC (×109/L) | 4.37 (2.44) | 3.30 (1.84) | .009 | 112 | |||||
Data are presented as mean (SD), median (IQR) or number (%), as appropriate.
ANC, absolute neutrophil count; BV, brentuximab vedotin; CAD, cyclophosphamide, doxorubicin; CHO(E)P, cyclophosphamide, doxorubicin, vincristine, (etoposide), prednisolone; CR, complete remission; DHAC, dexamethasone, cytarabine, carboplatin; HD ARA-C, high-dose cytarabine; IQR, interquartile range; PD, progressive disease; PR, partial remission; (R-)DHAP, (rituximab) dexamethasone, cytarabine, cisplatin; (R-)VIM, (rituximab) etoposide, iphosphamide, methotrexate; SD, standard deviation; VGPR, very good partial response; WBC, white blood cell count. Other chemomobilization regimens include: CYVE (cytarabine, etoposide), mini-BEAM (carmustine, etoposide, cytarabine, melphalan), AraC/TT (high dose cytarabine and thiotepa).
For lymphoma patients with stable disease or PD or PR.
Peripheral blood levels were recorded before start of the chemomobilization regimen.